Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity

Journal of Medicinal Chemistry

Volumn 49, Issue 18, 2006, Pages 5470-5477

  Pratt, David J ^a,d   Bentley, Jo ^b   Jewsbury, Philip ^c   Boyle, F Tom ^c   Endicott, Jane A ^a   Noble, Martin E M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d MRCLMB   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 CYCLOHEXYLMETHOXY 2 (4 SULFAMOYLANILINO)PURINE; 6 CYCLOHEXYLMETHOXY 2 (4' SULFAMOYLANILINO)PURINE; [(2 CHLORO 5 METHYLPHENYL)[6 [4 [3 (DIMETHYLAMINO) 2 HYDROXYPROPOXY]PHENYLAMINO]PYRIMIDIN 4 YL]AMINO]ACETONITRILE; ANILINE DERIVATIVE; ASPARTIC ACID; AZ 2; BISANILINOPYRIMIDINE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; HISTIDINE; LEUCINE; LYSINE; MUTANT PROTEIN; PHENYLALANINE; PYRIMIDINE DERIVATIVE; THREONINE; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SEQUENCE; ARTICLE; CELL CYCLE REGULATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ASSAY; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME SPECIFICITY; NONHUMAN; PROTEIN DETERMINATION; SITE DIRECTED MUTAGENESIS; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; MUTATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PURINES;

EID: 33748535123     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060216x     Document Type: Article

References (43)

1. Sherr, C. J. Cancer cell cycles. Science 1996, 274, (5293)), 1672-1677.
2. Malumbers, M.; Carnero, A. Cell cycle deregulation: a common motif in cancer. In Progress in Cell Cycle Research; Meijer, L.; Jézéquel, A., Roberge, M., Eds.; 2003; Vol. 5, pp 5-18.
3. Swanton, C. Cell-cycle targeted therapies. Lancet Oncol. 2004, 5, (1), 27-36.
4. Donnellan, R.; Chetty, R. Cyclin D1 and human neoplasia. Mol. Pathol. 1998, 51, (1)), 1-7.
5. Ruas, M.; Peters, G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta 1998, 1378, (2)), F115-77.
6. Morgan, D. O. Cyclin-dependent kinases: Engines, Clocks and Microprocessors. Annu. Rev. Cell Dev. Biol. 1997, 13, 261-291.
7. Catzavelos, C.; Bhattacharya, N.; Ung, Y. C.; Wilson, J. A.; Roncari, L.; Sandhu, C.; Shaw, P.; Yeger, H.; Morava-Protzner, I.; Kapusta, L.; Franssen, E.; Pritchard, K. I.; Slingerland, J. M. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 1997, 3 (2), 227-230.
8. Porter, P. L.; Malone, K. E.; Heagerty, P. J.; Alexander, G. M.; Gatti, L. A.; Firpo, E. J.; Daling, J. R.; Roberts, J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 1997, 3, (2), 222-225.
9. Keyomarsi, K.; Tucker, S. L.; Buchholz, T. A.; Callister, M.; Ding, Y.; Hortobagyi, G. N.; Bedrosian, I.; Knickerbocker, C.; Toyofuku, W.; Lowe, M.; Herliczek, T. W.; Bacus, S. S. Cyclin E and survival in patients with breast cancer N. Engl. J. Med. 2002, 347 (20), 1566-1575.
10. Pagano, M.; Tam, S. W.; Theodoras, A. M.; Beer-Romero, P.; Del Sal, G.; Chau, V.; Yew, P. R.; Draetta, G. F.; Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269 (5224), 682-685.
11. Hardcastle, I.-R.; Golding, B.-T.; Griffin, R.-J. Designing inhibitors of cyclin-dependent kinases. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 325-348.
12. Barvian, M.; Boschelli, D. H.; Cossrow, J.; Dobrusin, E.; Fattaey, A.; Fritsch, A.; Fry, D.; Harvey, P.; Keller, P.; Garrett, M.; La, F.; Leopold, W.; McNamara, D.; Quin, M.; Trumpp-Kallmeyer, S.; Toogood, P.; Wu, Z.; Zhang, E. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. 2000, 43 (24), 4606-4616.
13. Soni, R.; Muller, L.; Furet, P.; Schoepfer, J.; Stephan, C.; Zumstein-Mecker, S.; Fretz, H.; Chaudhuri, B. Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem. Biophys. Res. Commun. 2000, 275, (3)), 877-884.
14. Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida, T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J. Med. Chem. 2001, 44, (26)), 4615-4627.
15. CCP4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 1994, 50, 760-763.
16. De Bondt, H. L.; Rosenblatt, J.; Jancarik, J.; Jones, H. D.; Morgan, D. O.; Kim, S.-H. Crystal structure of cyclin-dependent kinase 2. Nature 1993, 363, 595-602.
17. Russo, A. A.; Jeffrey, P. D.; Pavletich, N. P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. 1996, 3 (8), 696-700.
18. Davies, T.-G.; Bentley, J.; Arris, C.-E.; Boyle, F. T.; Curtin, N.-J.; Endicott, J.-A.; Gibson, A.-E.; Golding, B.-T.; Griffin, R.-J.; Hardcastle, I.-R.; Jewsbury, P.; Johnson, L.-N.; Mesguiche, V.; Newell, D.-R.; Noble, M.-E. M.; Tucker, J.-A.; Wang, L.; Whitfield, H.-J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol. 2002, 9 (10), 745-749.
19. Gray, N. S.; Wodicka, L.; Thunnissen, A. M.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S. H.; Lockhart, D. J.; Schultz, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998, 281 (5376), 533-538.
20. Davies, T. G.; Tunnah, P.; Meijer, L.; Marko, D.; Eisenbrand, G.; Endicott, J. A.; Noble, M. E. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure (Camb) 2001, 9 (5), 389-397.
21. Meijer, L.; Thunnissen, A. M.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L. H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Kim, S. H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 2000, 7 (1), 51-63.
22. Davis, S. T.; Benson, B. G.; Bramson, H. N.; Chapman, D. E.; Dickerson, S. H.; Dold, K. M.; Eberwein, D. J.; Edelstein, M.; Frye, S. V.; Gampe, R. T., Jr.; Griffin, R. J.; Harris, P. A.; Hassell, A. M.; Holmes, W. D.; Hunter, R. N.; Knick, V. B.; Lackey, K.; Lovejoy, B.; Luzzio, M. J.; Murray, D.; Parker, P.; Rocque, W. J.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 2001, 291 (5501), 134-137.
23. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 2000, 43 (1), 133-138.
24. Lawrie, A. M.; Noble, M. E. M.; Tunnah, P. R.; Brown, N. R.; Johnson, L. N.; Endicott, J. A. Protein kinase inhibition by staurosporine: details of the molecular interaction determined by X-ray crystallographic analysis of a CDK2-staurosporine complex. Nat. Struct. Biol. 1997, 4, 796-801.
25. Holm, L.; Sander, C. Removing near-neighbour redundancy from large protein sequence collections. Bioinformatics 1998, 14 (5), 423-429.
26. Altschul, S. F.; Gish, W.; Miller, W.; Myers, E. W.; Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 1990, 215, (3), 403-410.
27. Thompson, J. D.; Higgins, D. G.; Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22 (22), 4673-4680.
28. Fisher, C. L.; Pei, G. K. Modification of a PCR Based Site-Directed Mutagenesis Method. BioTechniques 1997, 23, 570-574.
29. Brown, N. R.; Noble, M. E. M.; Endicott, J. E.; Johnson, L. N. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. 1999, 1 (7), 438-443.
30. Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J. J.; Donella-Deana, A.; Pinna, L.; Letham, D. S.; Kato, J.-Y.; Detivaud, L.; Leclerc, S.; Meijer, L. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 1994, 224, 771-786.
31. Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data Joint CCP4 and ESF-EAMCB. Newsl. Protein Crystallogr. 1992, 26.
32. Evans, P. R. Data Reduction; Science and Engineering Research Council UK: Daresbury Laboratory, Warrington, 1993; pp 114-122.
33. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-liklihood method. Acta Crystallogr. D 1997, 53, 240-255.
34. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard. Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 1991, 47 (2), 110-119.
35. Perrakis, A.; Morris, R.; Lamzin, V. S. Automated protein model building combined with iterative structure refinement. Nat. Struct. Biol. 1999, 6 (5), 458-463.
36. Beattie, J. F.; Breault, G. A.; Ellston, R. P.; Green, S.; Jewsbury, P. J.; Midgley, C. J.; Naven, R. T.; Minshull, C. A.; Pauptit, R. A.; Tucker, J. A.; Pease, J. E. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-Bis anilino pyrimidines. Bioorg. Med. Chem. Lett. 2003, 13 (18), 2955-2960.
37. Breault, G. A.; Ellston, R. P.; Green, S.; James, S. R.; Jewsbury, P. J.; Midgley, C. J.; Pauptit, R. A.; Minshull, C. A.; Tucker, J. A.; Pease, J. E. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines. Bioorg. Med. Chem. Lett. 2003, 13 (18), 2961-2966.
38. Honma, T.; Yoshizumi, T.; Hashimoto, N.; Hayashi, K.; Kawanishi, N.; Fukasawa, K.; Takaki, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S.; Morishima, H. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J. Med. Chem. 2001, 44 (26), 4628-4640.
39. Ikuta, M.; Kamata, K.; Fukasawa, K.; Honma, T.; Machida, T.; Hirai, H.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S. Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. J. Biol. Chem. 2001, 276 (29), 27548-2754.
40. Hardcastle, I. R.; Arris, C. E.; Bentley, J.; Boyle, F. T.; Chen, Y.; Curtin, N. J.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Jewsbury, P.; Menyerol, J.; Mesguiche, V.; Newell, D. R.; Noble, M. E.; Pratt, D. J.; Wang, L. Z.; Whitfield, H. J. N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. J. Med. Chem. 2004, 47 (15), 3710-3722.
41. Fabian, M. A.; Biggs, W. H., 3rd; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23 (3), 329-336.
42. Potterton, L.; McNicholas, S.; Krissinel, E.; Gruber, J.; Cowtan, K.; Emsley, P.; Murshudov, G. N.; Cohen, S.; Perrakis, A.; Noble, M. Developments in the CCP4 molecular-graphics project. Acta Crystallogr. D Biol. Crystallogr. 2004, 60 (Pt 12, Pt 1), 2288-2294.
43. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.